Last reviewed · How we verify
FCN-411 Dose-escalation
At a glance
| Generic name | FCN-411 Dose-escalation |
|---|---|
| Also known as | EGFR-TKI |
| Sponsor | Ahon Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase I Study of FCN-411 in Advanced Non-small Cell Lung Cancer Chinese Patients With EGFR Positive Mutation (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FCN-411 Dose-escalation CI brief — competitive landscape report
- FCN-411 Dose-escalation updates RSS · CI watch RSS
- Ahon Pharmaceutical Co., Ltd. portfolio CI